Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 8/20 | 0.52 |
| ▸ | RARG | P13631 | 7/20 | 0.52 |
| ▸ | RARA | P10276 | 5/20 | 0.52 |
| ▸ | CYP26A1 | O43174 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.52 |
| ▸ | RXRA | P19793 | 10/20 | 0.49 |
| ▸ | RXRB | P28702 | 6/20 | 0.49 |
| ▸ | RXRG | P48443 | 5/20 | 0.49 |
| ▸ | CYP26B1 | Q9NR63 | 3/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7751295 | 0.99 | RARB (0.51) | RARBRARGRARACYP26A1CYP3A4 | |
| Diethanolamine SCHEMBL7753391 | 0.92 | RARB (0.45) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL7753400 | 0.89 | RARG (0.43) | RARBRARGRARACYP26A1CYP3A4 | |
| Lithium Ion SCHEMBL7751288 | 0.89 | CYP26A1 (0.44) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL7746475 | 0.88 | RARG (0.55) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL7752278 | 0.88 | CYP3A4 (0.44) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL7751252 | 0.88 | CYP26A1 (0.44) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL7751144 | 0.87 | RXRA (0.40) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL19342932 | 0.86 | RARB (0.68) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL7751123 | 0.86 | RXRA (0.46) | RARBRARGRARACYP26A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686386-B1 | COMBATING PHOTOINDUCED OR CHRONOLOGICAL AGEING OF SKIN WITH RETENOIC ACID RECEPTOR AGONIST | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-03 | — | — | US | claimed |
| US-6593359-B1 | Pharmaceutical composition for increasing the rate of apoptosis in at least one cell population in which apoptosis may be induced by activating gamma -RAR receptors is disclosed. | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIOUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 2003-07-15 | — | — | US | claimed |
| US-6313162-B1 | FOR USE IN HUMAN OR VETERINARY MEDICINE SUCH AS DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR AND OPHHALMOLOGICAL DISORDERS; AND IN COSMETICS | CENTRE INTERNATIONAL DE RECHERCHE DERMATOLOGIQUES GALDERMA (C.I.R.D.) GALDERMA (FR) | 2001-11-06 | — | — | US | claimed |
| US-20010018456-A1 | Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis | FESUS LASZLO (HU) | 2001-08-30 | — | — | US | claimed |
| EP-0832057-B1 | DIAROMATIC PROPYNYL OR DIENYL COMPOUNDS | CT INTERNAT DE (FR) | 2001-01-03 | — | — | EP | claimed |
| US-6046220-A | ADMINISTERING TO THE PATIENT A PROPYNYL OR DIENYL BIAROMATIC COMPOUND TO TREAT A SKIN DISORDER, INFLAMMATORY CONDITIONS, VISION DEFECTS, ALOPECIA, CARDIOVASCULAR DISORDER, CANCER OR PRECANCER AND INSULIN DEPENDANT DIABETES | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2000-04-04 | — | — | US | claimed |
| US-6001885-A | INHIBITING VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) EXPRESSION IN KERATINOCYTES BY ADMINISTERING AT LEAST ONE RETINOID; USEFUL FOR TREATING DISEASES RELATING TO VEGF OVEREXPRESSION, SUCH AS PSORIASIS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (FR) | 1999-12-14 | — | — | US | claimed |
| EP-0832057-A1 | DIAROMATIC PROPYNYL OR DIENYL COMPOUNDS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 1998-04-01 | — | — | EP | claimed |
| WO-1997033856-A1 | DIAROMATIC PROPYNYL OR DIENYL COMPOUNDS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 1997-09-18 | — | — | WO | claimed |
| US-20050112123-A1 | Methods of treating proteinuria | WASHINGTON, UNIVERSITY OF | 2005-05-26 | — | — | US | disclosed |
| US-6686386-B1 | COMBATING PHOTOINDUCED OR CHRONOLOGICAL AGEING OF SKIN WITH RETENOIC ACID RECEPTOR AGONIST | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-03 | — | — | US | disclosed |
| US-6593359-B1 | Pharmaceutical composition for increasing the rate of apoptosis in at least one cell population in which apoptosis may be induced by activating gamma -RAR receptors is disclosed. | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIOUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 2003-07-15 | — | — | US | disclosed |
| US-20030092758-A1 | Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 2003-05-15 | — | — | US | disclosed |
| US-6506796-B1 | Cosmetically or therapeutically treating diseases or disorders in cell populations whose pathology is linked to an inadequate rate of apoptosis by administering a therapeutically effective amount of | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2003-01-14 | — | — | US | disclosed |
| US-20010018456-A1 | Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis | FESUS LASZLO (HU) | 2001-08-30 | — | — | US | disclosed |
| EP-0832057-B1 | DIAROMATIC PROPYNYL OR DIENYL COMPOUNDS | CT INTERNAT DE (FR) | 2001-01-03 | — | — | EP | disclosed |
| US-6046220-A | ADMINISTERING TO THE PATIENT A PROPYNYL OR DIENYL BIAROMATIC COMPOUND TO TREAT A SKIN DISORDER, INFLAMMATORY CONDITIONS, VISION DEFECTS, ALOPECIA, CARDIOVASCULAR DISORDER, CANCER OR PRECANCER AND INSULIN DEPENDANT DIABETES | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2000-04-04 | — | — | US | disclosed |
| US-6001885-A | INHIBITING VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) EXPRESSION IN KERATINOCYTES BY ADMINISTERING AT LEAST ONE RETINOID; USEFUL FOR TREATING DISEASES RELATING TO VEGF OVEREXPRESSION, SUCH AS PSORIASIS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (FR) | 1999-12-14 | — | — | US | disclosed |
| EP-0832057-A1 | DIAROMATIC PROPYNYL OR DIENYL COMPOUNDS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 1998-04-01 | — | — | EP | disclosed |
| WO-1997033856-A1 | DIAROMATIC PROPYNYL OR DIENYL COMPOUNDS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 1997-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092758-A1 | Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis | RARA, RARB, RARG | RARB 2/4885RARG 3/4885RARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.